CD19 and B-cell chronic lymphocytic leukemia: It increases the persistence of activated T cells in vivo, reduces the Treg/CD4+ T cell ratio, diminishes CLL cell immunosuppression, and enhances CD19-directed CAR T-cell expansion while decreasing CRS [175,176].